Scarica l'app Stockscreener
252.55
2.78%
6.82
Dopo l'orario di chiusura:
252.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$245.73
Aprire:
$247.16
Volume 24 ore:
970.95K
Relative Volume:
0.93
Capitalizzazione di mercato:
$36.79B
Reddito:
$5.40B
Utile/perdita netta:
$1.49B
Rapporto P/E:
24.96
EPS:
10.1168
Flusso di cassa netto:
$1.78B
1 W Prestazione:
-7.02%
1M Prestazione:
-0.83%
6M Prestazione:
-12.39%
1 anno Prestazione:
+5.46%
Intervallo 1D:
$246.21
$254.21
Intervallo di 1 settimana:
$245.65
$277.67
Portata 52W:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
252.55 | 35.80B | 5.40B | 1.49B | 1.78B | 10.12 |
|
ISRG
Intuitive Surgical Inc
|
485.84 | 169.97B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
175.89 | 50.58B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
79.20 | 38.58B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
44.55 | 37.11B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Why analysts raise outlook for ResMed Inc. (RME) stockSwing Trade & Smart Money Movement Tracker - mfd.ru
Rhumbline Advisers Boosts Position in ResMed Inc. $RMD - MarketBeat
Envestnet Asset Management Inc. Raises Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CPAP Headgear Market to See Thriving Worldwide | ResMed • Philips Respironics • Fisher & Paykel Healthcare - openPR.com
Dr Boreham’s Crucible: A rival may be circling, but ResMed isn’t losing any sleep - Stockhead
ResMed Tests Smart CPAP Pressure Tool in New Sleep Apnea Trial - TipRanks
ResMed (RMD) Valuation Check After Strong Earnings And Dividend Update - Yahoo Finance
Is It Time To Reassess ResMed (RMD) After Recent Medical Devices Sector Interest - Yahoo Finance
Resmed launches AirTouch F30i Comfort full-face fabric mask - MassDevice
Baader Bank Aktiengesellschaft Sells 8,794 Shares of ResMed Inc. $RMD - MarketBeat
Michael Farrell Sells 4,991 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
Zacks.com featured highlights include Amphenol, GE Aerospace, ResMed and Ameriprise Financial - The Globe and Mail
ResMed CEO Farrell sells $1.36 million in stock By Investing.com - Investing.com Canada
ResMed Inc (RMD)'s Winning Formula: Financial Metrics and Compet - GuruFocus
ResMed’s Profitability Surge Driven by Operational Gains - AD HOC NEWS
With 73% ownership in ResMed Inc. (NYSE:RMD), institutional investors have a lot riding on the business - Yahoo Finance
ResMed General Counsel Sells Shares Under Pre-Set Trading Plan - TipRanks
ResMed Director Reports Changes in Stock Ownership - MSN
Why You Might Be Interested In ResMed Inc. (NYSE:RMD) For Its Upcoming Dividend - simplywall.st
ResMed (NYSE:RMD) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
Insider Sell: Michael Rider Sells Shares of ResMed Inc (RMD) - GuruFocus
Resmed director Farrell sells $502k in stock By Investing.com - Investing.com Nigeria
Resmed: global general counsel Rider sells $13,000 in stock By Investing.com - Investing.com Australia
Resmed director Farrell sells $502k in stock - Investing.com
ResMed (NYSE:RMD) General Counsel Sells $13,000.00 in Stock - MarketBeat
ResMed (NYSE:RMD) Director Sells $502,620.00 in Stock - MarketBeat
Smart Sand, Inc. Achieves 140.93% Return, Outperforming NetApp and ResMed - Markets Mojo
RMD Stock Up Following Q2 Earnings & Revenue Beat, Margins Expand - TradingView
Resmed: global general counsel Rider sells $13,000 in stock - Investing.com
ResMed Chief Legal Officer Sells 50 Common Shares Of Firm - marketscreener.com
ResMed Director Sells 2,000 Shares - marketscreener.com
Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today - The Motley Fool Australia
ResMed Inc (RMD) Stock Price Down 0% on Feb 5 - GuruFocus
The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call - The Globe and Mail
The Top 5 Analyst Questions From ResMed's Q4 Earnings Call - Finviz
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) Gets a Buy from UBS - The Globe and Mail
ResMed Deepens CPAP Lead As Wearables And Digital Tools Expand Reach - Yahoo Finance
ResMed Adjusts CDI and Share Balances Amid Ongoing Capital Management - TipRanks
What can investors expect from ResMed, Cochlear and CSL shares this reporting season? - The Motley Fool Australia
Allianz Asset Management GmbH Acquires 110,647 Shares of ResMed Inc. $RMD - MarketBeat
WCM Investment Management LLC Makes New Investment in ResMed Inc. $RMD - MarketBeat
ResMed Slipped 1% on Profit Beat: Is $400 the 2026 Recovery Target? - TIKR.com
The Truth About ResMed Inc.: Why Everyone Is Suddenly Paying Attention - AD HOC NEWS
ResMed At Wearable And AI Turning Point In Sleep Apnea Care - Sahm
Insider Sell Alert: Brett Sandercock Sells Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells 1,000 Shares Under Pre-Set Trading Plan - TipRanks
ChartWatch ASX Scans: Appen, Aussie Broadband, Flight Centre Travel, Resmed, Siteminder, Sunrise Energy Metals - Market Index
Resmed Founder Receives 2026 Horatio Alger Award - respiratory-therapy.com
Zacks Industry Outlook Highlights Boston Scientific, ResMed, Phibro Animal Health and BioLife Solutions - Yahoo Finance
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.09%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):